Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGSWW) Enterprise Value (2020 - 2025)

GeneDx Holdings has reported Enterprise Value over the past 6 years, most recently at -$171.3 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$171.3 million for Q4 2025, down 21.32% from a year ago — trailing twelve months through Dec 2025 was -$171.3 million (down 21.32% YoY), and the annual figure for FY2025 was -$171.3 million, down 21.32%.
  • Enterprise Value for Q4 2025 was -$171.3 million at GeneDx Holdings, down from -$155.1 million in the prior quarter.
  • Over the last five years, Enterprise Value for WGSWW hit a ceiling of $236.1 million in Q1 2021 and a floor of -$461.3 million in Q3 2021.
  • Median Enterprise Value over the past 5 years was -$148.1 million (2024), compared with a mean of -$164.0 million.
  • Biggest five-year swings in Enterprise Value: plummeted 40363.55% in 2021 and later skyrocketed 69.06% in 2022.
  • GeneDx Holdings' Enterprise Value stood at -$400.6 million in 2021, then skyrocketed by 69.06% to -$123.9 million in 2022, then dropped by 5.01% to -$130.1 million in 2023, then dropped by 8.48% to -$141.2 million in 2024, then fell by 21.32% to -$171.3 million in 2025.
  • The last three reported values for Enterprise Value were -$171.3 million (Q4 2025), -$155.1 million (Q3 2025), and -$134.6 million (Q2 2025) per Business Quant data.